5月16日,复宏汉霖(02696)发布公告,近日自主研发的伊匹木单抗生物类似药HLX13(重组抗CTLA-4全人单克隆抗体注射液)一线治疗不可切除的晚期肝细胞癌患者的1/3期临床研究在中国境内完成首例患者给药。该研究为多中心、随机、双盲、平行对照的1/3期临床研究,旨在评估HLX13与其原研药YERVOY®在既往未治疗的不可切除晚期肝细胞癌患者中的药代动力学特征、有效性、安全性和免疫原性相似性。...
Source Link5月16日,复宏汉霖(02696)发布公告,近日自主研发的伊匹木单抗生物类似药HLX13(重组抗CTLA-4全人单克隆抗体注射液)一线治疗不可切除的晚期肝细胞癌患者的1/3期临床研究在中国境内完成首例患者给药。该研究为多中心、随机、双盲、平行对照的1/3期临床研究,旨在评估HLX13与其原研药YERVOY®在既往未治疗的不可切除晚期肝细胞癌患者中的药代动力学特征、有效性、安全性和免疫原性相似性。...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.